All In Biotech

Drug Trial Radar · NCT06147414

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Evaluation of the Diagnostic Performance of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Oct 23, 2024

Primary completion

May 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
URC-CIC Paris Descartes Necker Cochin
First posted
Nov 27, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnosis for single-gene disorders (SGD-NIPD). This can be performed from 9 weeks of amenorrhea and offers an early, safe and accurate definitive diagnosis without the miscarriage risk associated with invasive procedures. One of the major difficulties is distinguishing fetal genotype in the high background of maternal cfDNA, which leads to several technical and analytical challenges. Besides, unlike noninvasive prenatal testing for aneuploidy, NIPD for monogenic diseases represent a smaller market opportunity, and many cases must be provided on a bespoke, patient- or disease-specific basis. As a result, implementation of SGD-NIPD remained sparse, with most testing being delivered in a research setting. The present project aims to take advantage of the unique French collaborative network to make SGD-NIPD possible for theoretically any monogenic disorder and any family.

Conditions

  • Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including
  • Sickle Cell Disease
  • Cystic Fibrosis
  • Fragile X Syndrome
  • Proximal Spinal Muscular Atrophy
  • Myotonic Dystrophy
  • Muscular Dystrophy, Duchenne
  • Muscular Dystrophy, Becker
  • Neurofibromatosis-Noonan Syndrome
  • Huntington Disease
  • Hemophilia A
  • Hemophilia B
  • MODY2 Diabetes
  • X-Linked Hydrocephalus
  • Autosomal Recessive Polycystic Kidney Disease

Interventions

  • Blood sampleBiological

    A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study. The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes). During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers). The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. % of affected/unaffected fetuses that were correctly classified as affected/unaffectedTime frame: 1 day
  2. % of inconclusive resultsTime frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpital Cochin, Maternité Port-Royal, service de Gynécologie obstétrique

    Paris, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.